Ligand Pharmaceuticals (LGND) Net Cash Flow (2010 - 2026)

Ligand Pharmaceuticals (LGND) has 17 years of Net Cash Flow data on file, last reported at -$59.8 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow fell 136.34% year-over-year to -$59.8 million; the trailing twelve-month figure through Mar 2026 stood at $65.8 million (up 3538.0% YoY), and the FY2025 full-year result was $100.3 million, up 98.44% from the prior year.
• Net Cash Flow fell to -$59.8 million in Q1 2026, from $36.1 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $69.3 million in Q3 2025 to a low of -$60.3 million in Q2 2023.
• A 5-year average of $5.6 million and a median of $3.1 million in 2023 frame the typical range for Net Cash Flow.
• Across the five-year window, Net Cash Flow soared 1146.58% in 2022 and sank 637.71% in 2023, its largest moves.
• Tracing LGND's Net Cash Flow over 5 years: stood at $40.9 million in 2022, then slumped by 92.43% to $3.1 million in 2023, then jumped by 230.62% to $10.2 million in 2024, then jumped by 253.08% to $36.1 million in 2025, then tumbled by 265.43% to -$59.8 million in 2026.
• Business Quant data shows LGND's Net Cash Flow at -$59.8 million in Q1 2026, $36.1 million in Q4 2025, and $69.3 million in Q3 2025.